Sartorius Community

XTRA:SRT3 Community

1 Narratives written by author
0 Comments on narratives written by author
9 Fair Values set on narratives written by author

AN

AnalystConsensusTarget

Consensus Narrative from 20 Analysts

Acquisition And Cost Control Will Secure Future Success

Key Takeaways Acquisition of MatTek enhances preclinical services, boosting revenues and market positioning through reduced reliance on animal testing and expanded offerings. Strong recurring consumables growth and efficiency programs drive margin expansion, positioning Sartorius for future earnings growth and financial stability.

€268.45

FV

14.3% undervalued

9.31%

Revenue growth p.a.

0

0

6

Updated